Revenue: As of FY2025 Q1, the actual value is USD 8.588 M.EPS: As of FY2025 Q1, the actual value is USD -0.47.EBIT: As of FY2025 Q1, the actual value is USD -4.069 M.<h3>Segment Revenue</h3><ul><li>Total Revenues, Net: $8,588 thousand for the three months ended March 31, 2025, compared to $7,912 thousand for the same period in 2024, representing an increase of $676 thousand.</li></ul><h3>Operational Metrics</h3><ul><li>Cost of Revenues, Related Party: $3,075 thousand for the three months ended March 31, 2025, compared to $3,946 thousand for the same period in 2024, a decrease of $871 thousand.</li><li>Selling, General and Administrative Expenses: $8,653 thousand for the three months ended March 31, 2025, compared to $9,250 thousand for the same period in 2024, a decrease of $597 thousand.</li><li>Research and Development Expenses: $1,207 thousand for the three months ended March 31, 2025, compared to $17 thousand for the same period in 2024, an increase of $1,190 thousand.</li><li>Net Loss: $4,203 thousand for the three months ended March 31, 2025, compared to $10,437 thousand for the same period in 2024, a decrease in net loss of $6,234 thousand.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $4,117 thousand for the three months ended March 31, 2025, compared to - $3,325 thousand for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $3 thousand for the three months ended March 31, 2025.</li><li>Net Cash Provided by Financing Activities: $0 for the three months ended March 31, 2025, compared to $5,799 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to expand the commercialization of Ameluz® in the United States while controlling expenses and limiting capital expenditures. The company also aims to capitalize on the reduced cost of inventory in line with the terms of the Second A&amp;R Ameluz LSA.</li><li>Non-Core Business: The company is working with a potential purchaser to complete a sale of the Xepi product line within the next one to five months.</li></ul>

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 8.588 M